Martin Rowe

21.9k total citations · 4 hit papers
199 papers, 17.5k citations indexed

About

Martin Rowe is a scholar working on Oncology, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Martin Rowe has authored 199 papers receiving a total of 17.5k indexed citations (citations by other indexed papers that have themselves been cited), including 168 papers in Oncology, 86 papers in Pathology and Forensic Medicine and 72 papers in Immunology. Recurrent topics in Martin Rowe's work include Viral-associated cancers and disorders (163 papers), Lymphoma Diagnosis and Treatment (82 papers) and Immune Cell Function and Interaction (53 papers). Martin Rowe is often cited by papers focused on Viral-associated cancers and disorders (163 papers), Lymphoma Diagnosis and Treatment (82 papers) and Immune Cell Function and Interaction (53 papers). Martin Rowe collaborates with scholars based in United Kingdom, United States and Germany. Martin Rowe's co-authors include Alan B. Rickinson, Lawrence S. Young, Debbie Croom-Carter, Elliott Kieff, C D Gregory, S. A. Henderson, David Huen, A. B. Rickinson, Gorm Pallesen and J. Eike Floettmann and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Martin Rowe

198 papers receiving 17.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Induction of bcl-2 expression by epstein-barr virus latent membrane protein 1 protects infected B cells from programmed cell death

1991 1.0k citations S. A. Henderson, Martin Rowe et al. profile →
Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease

1991 589 citations Martin Rowe, Lawrence S. Young et al. profile →
Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells.

1987 588 citations Martin Rowe, Lawrence S. Young et al. profile →
Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23

1990 496 citations C D Gregory, Martin Rowe et al. Journal of Virology profile →

Peers

Countries citing papers authored by Martin Rowe

Since Specialization

Citations

This map shows the geographic impact of Martin Rowe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Rowe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Rowe more than expected).

Fields of papers citing papers by Martin Rowe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Rowe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Rowe. The network helps show where Martin Rowe may publish in the future.

Co-authorship network of co-authors of Martin Rowe

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Rowe. A scholar is included among the top collaborators of Martin Rowe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Rowe. Martin Rowe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Innate Immune Recognition of EBV 2015 ·Current topics in microbiology and immunology ·Anna Lünemann, Martin Rowe, David Nadal	31
2	Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53 2014 ·Genes & Development ·Gemma L. Kelly, Stephanie Grabow, Stefan Glaser, Leah Fitzsimmons, Brandon J. Aubrey, Toru Okamoto, Liz J. Valente, Mikara Robati, Lin Tai, W. Douglas Fairlie, Erinna F. Lee, Mikael S. Lindström, Klas G. Wiman, David C.S. Huang, Philippe Bouillet, Martin Rowe, Alan B. Rickinson, Marco J. Herold, Andreas Strasser	126
3	Summary of roundtable discussion meeting: Non-human primates to assess risk for EBV-related lymphomas in humans 2011 ·Journal of Immunotoxicology ·Thomas T. Kawabata, James L. Weaver, Dolca Thomas, Martin Rowe, Fred Wang, Cris Kamperschroer, Helen G. Haggerty	5
4	The Epstein-Barr Virus-Encoded BILF1 Protein Modulates Immune Recognition of Endogenously Processed Antigen by Targeting Major Histocompatibility Complex Class I Molecules Trafficking on both the Exocytic and Endocytic Pathways 2010 ·Journal of Virology ·Jianmin Zuo, Laura L. Quinn, Jennifer Tamblyn, Wendy A. Thomas, Regina Feederle, Henri‐Jacques Delecluse, Andrew D. Hislop, Martin Rowe	72
5	Cyclical Expression of EBV Latent Membrane Protein 1 in EBV-Transformed B Cells Underpins Heterogeneity of Epitope Presentation and CD8+ T Cell Recognition 2009 ·The Journal of Immunology ·Jill Brooks, Steven P. Lee, Alison M. Leese, Wendy A. Thomas, Martin Rowe, Alan B. Rickinson	26
6	Modulation of B-cell endoplasmic reticulum calcium homeostasis by Epstein-Barr virus Latent Membrane Protein-1 2009 ·Molecular Cancer ·Olivier Dellis, Atousa Arbabian, Jean‐Philippe Brouland, Tündé Kovàcs, Martin Rowe, Christine Chomienne, Irène Joab, Béla Papp	31
7	CD154 Tone Sets the Signaling Pathways and Transcriptome Generated in Model CD40-Pluricompetent L3055 Burkitt’s Lymphoma Cells 2007 ·The Journal of Immunology ·(unknown), Wenbin Wei, (unknown), Richard J. Armitage, John R. Arrand, Martin Rowe, Lawrence S. Young, Aristides G. Eliopoulos, John Gordon	14
8	Latent Membrane Protein 1 of Epstein-Barr Virus Stimulates Processing of NF-κB2 p100 to p52 2003 ·Journal of Biological Chemistry ·Peter G.P. Atkinson, (unknown), Martin Rowe, Steven C. Ley	64
9	Characterization of a CD40-Dominant Inhibitory Receptor Mutant 2001 ·The Journal of Immunology ·Anja M. Mehl, Matthew D. Jones, Martin Rowe, Paul Brennan	3
10	Epstein-Barr virus latent membrane protein-1 (LMP1) C-terminus activation region 2 (CTAR2) maps to the far C-terminus and requires oligomerisation for NF-κB activation 1997 ·Oncogene ·J. Eike Floettmann, Martin Rowe	105
11	Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised. 1995 ·The Journal of Experimental Medicine ·Ann B. Hill, (unknown), John S. Haurum, N. Murray, Q. Y. Yao, Martin Rowe, Nathalie Signoret, A. B. Rickinson, Andrew J. McMichael	81
12	Epstein-Barr-Virus Isolates From a Highly Hla A11 Positive Population Lack the Dominant A11 Restricted T-Cell Epitope 1993 ·Journal of Cellular Biochemistry ·(unknown), Riccardo Gavioli, Qingjiong Zhang, (unknown), Riccardo Dolcetti, Martin Rowe, A. B. Rickinson, Maria G. Masucci	3
13	Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. 1992 ·The Journal of Experimental Medicine ·R J Murray, Michael G. Kurilla, Jill Brooks, Wendy A. Thomas, Martin Rowe, E Kieff, Alan B. Rickinson	428
14	Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. 1991 ·The Journal of Experimental Medicine ·Martin Rowe, Lawrence S. Young, J Crocker, (unknown), S. A. Henderson, Alan B. Rickinson	263
15	Cross‐recognition of a mouse H‐2‐peptide complex by human HLA‐restricted cytotoxic T cells 1990 ·European Journal of Immunology ·R J Murray, Jill Brooks, Alan B. Rickinson, Martin Rowe	6
16	Establishment of an EBV‐positive lymphoblastoid cell line that grows as a lymphoma in nude mice and expresses membrane CD2 molecules 1990 ·International Journal of Cancer ·Silvio Roncella, Dunia Ramarli, (unknown), Marco Forni, (unknown), Martin Rowe, Paola Francia di Celle, Mario Sessarego, Robin Foà, G Forni, Peter D. Burrows, Vito Pistoia, Manlio Ferrarini	16
17	Effect of the ebna‐2 gene on the surface antigen phenotype of transfected ebv‐negative B‐lymphoma lines 1990 ·International Journal of Cancer ·Pierre Åman, Martin Rowe, Chieko Kai, Jürgen Finke, Lars Rymo, Eva Klein, (unknown)	21
18	Analysis of Epstein-Barr Virus Gene Expression in Lymphomas Derived from Normal Human B Cells Grafted into SCID Mice 1990 ·Current topics in microbiology and immunology ·Martin Rowe, Lawrence S. Young, Alan B. Rickinson	4
19	The epstein‐barr virus: Host balance in acute infectious mononucleosis patients receiving acyclovir anti‐viral therapy 1989 ·International Journal of Cancer ·Q. Y. Yao, (unknown), Martin Rowe, MacDonald Wood, Alan B. Rickinson	41
20	Burkitt-like lymphoma in an English child: Characterisation of tumour biopsy cells and of the derived tumour cell line 1986 ·British Journal of Cancer ·S. Finerty, Martin Rowe, P J Berry, David Ranson, M.G. Mott, C D Gregory, Alan B. Rickinson	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact